Executive Summary

For developers of gene-edited cell therapies, particularly those using CRISPR/Cas9 systems, a comprehensive viral shedding and biodistribution study is a mandatory component of any successful IND submission. The objective is to generate definitive, quantitative data on the persistence, clearance, and potential mobilization of the therapeutic product from the site of administration. Franklin Biolabs develops and validates custom qPCR and ddPCR assays to precisely quantify these materials in all relevant biological matrices, providing the robust safety data required by regulatory authorities. Our programs are designed to align with an 18-24 month IND timeline, supported by a >100,000 sq ft GxP-compliant facility.

Regulatory Expectations for Biodistribution and Shedding

IND-enabling studies for gene-edited cell therapies demand a clear characterization of the product’s behavior after administration. Regulators require data that demonstrates where the product goes, how long it persists, and whether it is shed from the body. This is not a perfunctory exercise: the data directly informs the risk assessment for both the patient and the general population.

An effective study design accounts for:

• Route of Administration: The administration route directly influences expected biodistribution patterns.

• Sample Matrices: A comprehensive panel of matrices (e.g., blood, urine, feces, saliva, tissue swabs) must be collected at multiple time points.

• Assay Sensitivity: The lower limit of quantification (LLOQ) must be sensitive enough to detect minimal amounts of shed material, providing confidence in negative results.

The Impact of Delivery Systems on Analytical Strategy

The method used to deliver gene-editing machinery, such as CRISPR-Cas9, has significant implications for the bioanalytical strategy. Advances in non-viral delivery, such as the use of branched ionizable lipids in LNPs to improve endosomal escape for ribonucleoprotein complexes, introduce new components that must be tracked (PMID: 39856035). While the final therapeutic may be an ex vivo edited cell, the biodistribution and clearance of manufacturing residuals or in vivo delivery vehicles require dedicated analytical methods. A robust IND package must account for all components, not just the final cellular product.

.*

GxP-Compliant Quantitative Assays

Franklin Biolabs provides fully validated, GxP-compliant qPCR and ddPCR assays tailored to your specific construct. Since our brand launch in 2024, programs we have managed have maintained a 100% IND success rate, a record established by our scientific leadership since 2019.

Our process includes:
1. In Silico Design: Bioinformatic analysis to identify unique target sequences in your construct for maximum specificity.
2. Assay Optimization: Rigorous testing to define optimal conditions for sensitivity and reproducibility.
3. GxP Validation: A formal validation process to document assay performance characteristics, including accuracy, precision, linearity, and specificity, for regulatory submission.
4. Sample Analysis: High-throughput analysis of preclinical study samples in our dedicated bioanalytical laboratories.